Recordati

pay deal hand over cash licensing transaction money
Pharma

Sanofi sells rare disease med Enjaymo to Recordati for $825M

Recordati is paying $825 million upfront—plus $250 million in potential milestones—to pick up the global rights to Sanofi’s rare disease med Enjaymo.
Fraiser Kansteiner Oct 4, 2024 10:11am
signing contract

Recordati to acquire EUSA Pharma for €750m ($845 million)

Dec 3, 2021 11:10am
approved

Recordati scores FDA nod for Cushing's disease med Isturisa

Mar 9, 2020 11:58am
Novartis headquarters

Novartis offloads endocrine drugs to Recordati for $390M

Jul 15, 2019 12:25pm
Handshake business deal executives

CVC revs up rare disease ambitions with $3.5B Recordati buy

Jul 2, 2018 11:05am
Italy

CVC weighs $3B-plus Recordati buy: FT

Jun 20, 2018 12:29pm